174 related articles for article (PubMed ID: 28253828)
1. Emerging protein kinase inhibitors for treating pancreatic cancer.
Furuse J; Nagashima F
Expert Opin Emerg Drugs; 2017 Mar; 22(1):77-86. PubMed ID: 28253828
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
3. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
[TBL] [Abstract][Full Text] [Related]
4. Targeting Epidermal Growth Factor Receptor-Related Signaling Pathways in Pancreatic Cancer.
Philip PA; Lutz MP
Pancreas; 2015 Oct; 44(7):1046-52. PubMed ID: 26355547
[TBL] [Abstract][Full Text] [Related]
5. Emerging antibodies for the treatment of pancreatic cancer.
Andrikou K; Peterle C; Pipitone S; Salati M; Cascinu S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):39-51. PubMed ID: 28253833
[TBL] [Abstract][Full Text] [Related]
6. An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Wang Z; Fu S
Expert Opin Investig Drugs; 2016; 25(1):15-30. PubMed ID: 26560712
[TBL] [Abstract][Full Text] [Related]
7. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
[TBL] [Abstract][Full Text] [Related]
8. MEK inhibitors in oncology: a patent review (2015-Present).
Mahapatra DK; Asati V; Bharti SK
Expert Opin Ther Pat; 2017 Aug; 27(8):887-906. PubMed ID: 28594589
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
10. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
11. Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.
Brauswetter D; Gurbi B; Varga A; Várkondi E; Schwab R; Bánhegyi G; Fábián O; Kéri G; Vályi-Nagy I; Peták I
PLoS One; 2017; 12(9):e0185687. PubMed ID: 28957417
[TBL] [Abstract][Full Text] [Related]
12. What's new in treatment of pancreatic cancer: a patent review (2010-2017).
Ramos MC; Boulaiz H; Griñan-Lison C; Marchal JA; Vicente F
Expert Opin Ther Pat; 2017 Nov; 27(11):1251-1266. PubMed ID: 28665163
[TBL] [Abstract][Full Text] [Related]
13. Small molecule tyrosine kinase inhibitors and pancreatic cancer-Trials and troubles.
Lakkakula BVKS; Farran B; Lakkakula S; Peela S; Yarla NS; Bramhachari PV; Kamal MA; Saddala MS; Nagaraju GP
Semin Cancer Biol; 2019 Jun; 56():149-167. PubMed ID: 30314681
[TBL] [Abstract][Full Text] [Related]
14. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
[TBL] [Abstract][Full Text] [Related]
15. Targeting protein kinase C subtypes in pancreatic cancer.
Storz P
Expert Rev Anticancer Ther; 2015 Apr; 15(4):433-8. PubMed ID: 25604078
[TBL] [Abstract][Full Text] [Related]
16. Novel mitogen-activated protein kinase kinase inhibitors.
Chapman MS; Miner JN
Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
[TBL] [Abstract][Full Text] [Related]
17. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
Wolin EM
Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer.
Sugarman R; Patel R; Sharma S; Plenker D; Tuveson D; Saif MW
Expert Opin Drug Metab Toxicol; 2019 Jul; 15(7):541-552. PubMed ID: 31241371
[No Abstract] [Full Text] [Related]
19. BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities.
Rizzo D; Ruggiero A; Amato M; Maurizi P; Riccardi R
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1397-1405. PubMed ID: 27494648
[TBL] [Abstract][Full Text] [Related]
20. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
